000			01807 a2200481 4500
005			20250516072123.0
264		0	_c20120618
008			201206s 0 0 eng d
022			_a1473-5571
024	7		_a10.1097/QAD.0b013e3283509826 _2doi
040			_aNLM _beng _cNLM
100	1		_aGarrido, Carolina
245	0	0	_aMechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. _h[electronic resource]
260			_bAIDS (London, England) _cMar 2012
300			_a551-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aADP-ribosyl Cyclase 1 _xdrug effects
650	0	4	_aAdult
650	0	4	_aAntiretroviral Therapy, Highly Active _xmethods
650	0	4	_aCD4 Lymphocyte Count
650	0	4	_aCase-Control Studies
650	0	4	_aFas Ligand Protein _xdrug effects
650	0	4	_aFlow Cytometry
650	0	4	_aHIV Infections _xdrug therapy
650	0	4	_aHIV Integrase Inhibitors _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aLeukocyte Common Antigens _xdrug effects
650	0	4	_aMiddle Aged
650	0	4	_aPlatelet Endothelial Cell Adhesion Molecule-1 _xdrug effects
650	0	4	_aPyrrolidinones _xtherapeutic use
650	0	4	_aRaltegravir Potassium
650	0	4	_aTNF-Related Apoptosis-Inducing Ligand _xdrug effects
650	0	4	_aTreatment Outcome
650	0	4	_aTumor Necrosis Factor Receptor Superfamily, Member 7 _xdrug effects
700	1		_aRallón, Norma
700	1		_aSoriano, Vincent
700	1		_aLopez, Mariola
700	1		_aZahonero, Natalia
700	1		_ade Mendoza, Carmen
700	1		_aBenito, Jose M
773	0		_tAIDS (London, England) _gvol. 26 _gno. 5 _gp. 551-7
856	4	0	_uhttps://doi.org/10.1097/QAD.0b013e3283509826 _zAvailable from publisher's website
999			_c21429339 _d21429339